15353-j-veluchamy

5 Towards UCB-NK cells treatment in colorectal cancer | 135 References 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin (2016) 66 (1):7-30. Epub 2016/01/09. doi: 10.3322/caac.21332. PubMed PMID: 26742998. 2. Fakih MG. Metastatic Colorectal Cancer: Current State and Future Directions. Journal of Clinical Oncology (2015). doi: 10.1200/jco.2014.59.7633. 3. Dozois EJ, Boardman LA, Suwanthanma W, Limburg PJ, Cima RR, Bakken JL, et al. Young-onset colorectal cancer in patients with no known genetic predisposition: can we increase early recognition and improve outcome? Medicine (2008) 87 (5):259-63. Epub 2008/09/17. doi: 10.1097/ MD.0b013e3181881354. PubMed PMID: 18794708; PubMed Central PMCID: PMCPMC4437192. 4. Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis. International journal of colorectal disease (2011) 26 (7):823-33. Epub 2011/02/03. doi: 10.1007/s00384-011-1149-0. PubMed PMID: 21286919. 5. Graham J, Muhsin M, Kirkpatrick P. Cetuximab. Nature reviews Drug discovery (2004) 3 (7):549-50. Epub 2004/07/27. doi: 10.1038/nrd1445. PubMed PMID: 15272498. 6. Karapetis C, Khambata-Ford S, Jonker D, O’Callaghan C, Tu D, Tebbutt N, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 359 (17):1757 - 65. PubMed PMID: doi:10.1056/NEJMoa0804385. 7. Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol (2015) 26 (1):13-21. Epub 2014/08/15. doi: 10.1093/annonc/mdu378. PubMed PMID: 25115304. 8. Garnock-Jones KP, Keating GM, Scott LJ. Trastuzumab: A review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. Drugs (2010) 70 (2):215-39. Epub 2010/01/30. doi: 10.2165/11203700-000000000-00000. PubMed PMID: 20108993. 9. Garcia-Foncillas J, Diaz-Rubio E. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2010) 12 (8):533-42. Epub 2010/08/17. doi: 10.1007/s12094-010-0551-3. PubMed PMID: 20709651. 10. Winter MC, Hancock BW. Ten years of rituximab in NHL. Expert opinion on drug safety (2009) 8 (2):223-35. Epub 2009/02/27. doi: 10.1517/14740330902750114. PubMed PMID: 19243307. 11. Wang W, Erbe AK, Hank JA, Morris ZS, Sondel PM. NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy. Frontiers in immunology (2015) 6 :368. doi: 10.3389/ fimmu.2015.00368. PubMed PMID: PMC4515552. 12. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nature immunology (2008) 9 (5):503-10. doi: http://www.nature.com/ni/journal/v9/n5/suppinfo/ ni1582_S1.html. 13. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol (2001) 19 . doi: 10.1146/annurev.immunol.19.1.197.